Forty-three new 1-oxa-3,8-diazaspiro[4,5]decan-2-ones optionally substituted with 2-(3-indolyl)ethyl, 3-(2-methoxyphenoxy)-2-hydroxypropyl, or 2-(1,4-benzodioxan 2-yl)-2-hydroxyethyl at the 8 position were prepared for screening as antihypertensive agents in the spontaneous hypertensive rat. For the 8-[2-(3-indolyl)ethyl] compounds the most active were those substituted in the 4 position, where activity
任选被2-(3-
吲哚基)乙基,3-(2-
甲氧基苯氧基)-2-羟丙基或2-取代的四十三个新的1-oxa-3,8-diazaspiro [4,5] decan-2-one制备在8位的(1,4-苯并
二恶烷2-基)-2-羟乙基,以筛选自发性高血压大鼠中的降压药。对于8- [2-(3-
吲哚基)乙基]化合物,活性最高的是在4位取代的那些,其中4-乙基化合物(1)的活性最大。8- [3-(2-
甲氧基苯氧基)-2-羟丙基]化合物的活性低于其
1,4-苯并二恶烷的对应物,后者是作为赤型和苏型非对映异构体的混合物进行测试的。4-乙基-8- [2-(
1,4-苯并二恶烷-2-基)-2-羟乙基]-取代的38和(S)-3-甲基-8- [3-(2-
甲氧基苯氧基)- 2-羟丙基]-取代的42被设计为混合的α-和β-
肾上腺素受体阻滞剂。这两种化合物都降低了血压,但没有提供作为β-
肾上腺素能阻滞剂的证据。检验8- [2-(3-
吲哚基)乙基]